GLP-1 Near Me: Every Legit Way to Get It, With Prices
Any US pharmacy can fill a GLP-1 medicines prescription; ask your local pharmacy to order it if it is not on the shelf. The lowest self-pay price is $149 a month, and the lowest pharmacy cash price we found is $149 a month at GoodRx.
- Lowest self-pay
- $149 a month
- Telehealth from, all in
- $223 a month
- Prescription
- Required
- Shortage
- Some products short
Half-life and weight loss, briefly
Half-life in days means the time your body needs to clear half of a dose. You will find it in section 12.3 of each FDA label.
A percent of body weight. Because trials, doses, and lengths differ, compare each one against the placebo on its page.
All the legit GLP-1 routes, ranked
| Route | Who it is for | What you pay |
|---|---|---|
| Ozempic: Novo Nordisk PAP | Household income at 200% of the federal poverty level or below | Free if approved |
| Trulicity: Lilly Cares | Household income at 300% of the federal poverty level or below | Free for up to 12 months |
| Ozempic: Through your doctor, with insurance plus the savings card | Commercial insurance that covers it | For up to 3 months, the cost may be as low as $25 each month |
| Wegovy: Go through your doctor with insurance and the savings card | Commercial insurance that covers it | As little as $25 a month |
| Mounjaro: Through your doctor, with insurance plus the savings card | Commercial insurance that covers it | You may pay as little as $25 for filling up to 3 months |
| Zepbound: Go through your doctor with insurance and the savings card | Commercial insurance that covers it | You may pay as little as $25 for filling up to 3 months |
| Foundayo: Get it from your doctor with insurance and the savings card | Commercial insurance that covers it | As little as $25 a month |
| Rybelsus: Through your doctor, with insurance plus the savings card | Commercial insurance that covers it | As little as $25 for a 1, 2 or 3-month fill |
| Trulicity: Through your doctor, with insurance plus the savings card | Commercial insurance that covers it | You may pay as little as $25 for filling up to 3 months |
Prices checked November 2026. Each price links back to the page it came from.
Sources: Novo Nordisk pricing, NovoCare, TrumpRx, rx.costco.com.
Who qualifies
A prescription is required for every GLP-1 sold in the US. A label gives the approved uses, and a prescriber selects one when writing the script:
- Along with diet and exercise habits, Ozempic lowers blood sugar in adults with type 2 diabetes.
- Heart attack, stroke or heart-related death risks are lower with Ozempic for adults who have type 2 diabetes and heart disease.
- Among adults with heart disease and either obesity or overweight, Wegovy lowers the chance of a heart attack, stroke, or death related to the heart.
- Long-term weight loss and keeping it off: Wegovy, used with diet and activity, for adults and children who have obesity, ages 12 and older.
- Mounjaro lowers blood sugar for adults and children with type 2 diabetes who are 10 and older, alongside diet and exercise habits.
- Mounjaro reduces the chance of a heart attack, stroke, or death related to the heart among high-risk adults with type 2 diabetes.
- Weight loss and keeping it off long term, with diet and activity: Zepbound for adults who have obesity, or who have overweight along with a condition linked to weight.
- Zepbound: Treats moderate to severe obstructive sleep apnea in adults with obesity.
- Weight loss and keeping it off long term, with diet and activity: Foundayo for adults who have obesity, or who have overweight along with a condition linked to weight.
- Rybelsus lowers blood sugar in adults living with type 2 diabetes, when used alongside diet and exercise habits.
- Rybelsus lowers the chance of heart attack, stroke or heart-related death among adults at high risk with type 2 diabetes.
- Trulicity lowers blood sugar for adults and children with type 2 diabetes who are 10 and older, alongside diet and exercise habits.
- Trulicity reduces the chance of heart attack, stroke or heart-related death in adults with type 2 diabetes and either heart disease or multiple heart risk factors.
- Used with diet and activity, Saxenda helps with weight loss and keeping the weight off long term. It is for people with obesity who are 12 and older (over 60 kg), or adults who have overweight and a weight-related problem.
- Victoza lowers blood sugar for adults and children with type 2 diabetes who are 10 and older, alongside diet and exercise habits.
- Heart attack, stroke or heart-related death risks are lower with Victoza for adults who have type 2 diabetes and heart disease.
Source: FDA label (DailyMed).
Telehealth compared
| Program | Medicine option | Medicine price | Membership | All in |
|---|---|---|---|---|
| Foundayo pill (self-pay) | $149 a month | $74 a month | $223 a month | |
| Wegovy pill (self-pay) | $149 a month | $74 a month | $223 a month | |
| Ozempic injectable pen (self-pay) | $199 a month | $74 a month | $273 a month | |
| Wegovy pill, starting dose | $149 a month | $149 a month | $298 a month | |
| Foundayo pill, starting dose | $149 a month | $149 a month | $298 a month | |
| Wegovy pill | $149 a month | $149 a month after first month | $298 a month | |
| Ozempic pen | $199 a month | $149 a month after first month | $348 a month | |
| Zepbound (self-pay) | $299 a month | $74 a month | $373 a month | |
| Sesame (Success by Sesame) | Wegovy or Ozempic pen, after intro months | $349 a month | $59 a month | $408 a month |
| Zepbound KwikPen, starting dose | $299 a month | $149 a month | $448 a month | |
| Wegovy pen, 1 mg to 2.4 mg | $349 a month | $149 a month | $498 a month | |
| Zepbound | $1,899 a month | $149 a month after first month | $2,048 a month | |
| Mounjaro | $1,899 a month | $149 a month after first month | $2,048 a month | |
| Compounded semaglutide (not FDA approved) | $60 a month | $79 a month after free first month | $139 a month | |
| Compounded tirzepatide (not FDA approved) | $90 a month | $79 a month after free first month | $169 a month | |
| Compounded liraglutide (daily injection) (not FDA approved) | $179 a month | Not listed | Included | |
| Tablets or drops containing compounded sublingual semaglutide, with no FDA approval | $179 a month | Not listed | Included | |
| Microdose GLP-1Rx Program (compounded) (not FDA approved) | $179 a month after the first 4 weeks, with quarterly billing | Not listed | Included | |
| GLP-1Rx Program (compounded semaglutide) (not FDA approved) | the cost is $249 a month after the first 4 weeks, with quarterly billing | Not listed | Included | |
| Compounded GLP-1 plan (not FDA approved) | $99 a month | $169 a month cash | $268 a month | |
| Compounded semaglutide (weekly injection) (not FDA approved) | $297 a month | Not listed | Included | |
| Compounded GLP-1 with GIP offered by the GLP-1Rx Plus Program, with no FDA approval | $299 a month after the first 4 weeks, with quarterly billing | Not listed | Included |
Each price comes from its program’s pricing page. None of them earns money for us
| Program | Membership | Type |
|---|---|---|
| $199 a month | insurance-first | |
| $19.99 a month | primary care membership | |
| $79 a month | brand only |
Sources: weightwatchers.com, ro.co, hims.com, sesamecare.com.
Shortage status
On February 21, 2025, the injection shortage for Semaglutide was resolved. Older Rybelsus tablets are being discontinued.
| Product | FDA status | Availability |
|---|---|---|
| Rybelsus tablet 3 mg, 7 mg, 14 mg | To Be Discontinued | Replaced by Ozempic (semaglutide) tablets |
- Its first listing on the FDA shortage list came in March 2022
- Shortage resolved: February 21, 2025
- State pharmacies had to stop making compounded copies on April 22, 2025
- Outsourcing facilities had to stop as of May 22, 2025
Tirzepatide: Its shortage has been resolved. The FDA confirmed this on December 19, 2024.
- The FDA shortage list first named it on December 15, 2022
- Shortage resolved: December 19, 2024
- State pharmacies had to stop making compounded copies by February 18, 2025
- Outsourcing facilities were required to stop as of March 19, 2025
The current FDA shortage data leaves out dulaglutide. Lilly says all Trulicity doses are available.
Current shortage listings still include liraglutide. Victoza pens have limited availability, though generics are available. In January 2027, Saxenda is being discontinued.
| Product | FDA status | Availability |
|---|---|---|
| Victoza 6 mg/mL pen (2-pack and 3-pack) | Current | Limited Availability |
| Victoza back order | Current | Back order |
| Saxenda 6 mg/mL pen (5-pack) | To Be Discontinued | Available until January 2027 |
| Generic liraglutide (Meitheal, Teva) | Current | Available |
- The FDA shortage list first named it on July 18, 2023
Sources: FDA, api.fda.gov, ashp.org.
Scam signals
- No prescription needed: a seller that skips it is not licensed as a pharmacy in the US.
- A brand sold far below the manufacturer's charges: its lowest self-pay price is $149 a month.
- Compounded drugs marketed as the brand carry no approval, so none of them is Zepbound, Ozempic, Wegovy, Mounjaro.
- Both semaglutide sodium and semaglutide acetate are different from the active ingredients used by approved drugs.
- Saying a drug is identical to the brand: FDA issued 30 warning letters to telehealth companies over misleading claims.
- Harm reports: the FDA holds 990 adverse event reports on file for compounded semaglutide.
- Harm reports: for compounded tirzepatide, the FDA holds more than 730 adverse event reports on file.
- The FTC acted against one program over a monthly price that leaves out the drug; see the NextMed review details.
Sources: Novo Nordisk pricing, NovoCare, TrumpRx, rx.costco.com.
Find it in your state
- Hims & Hers: Service is unavailable in some of the 50 states
- Noom Med: Does not serve all 50 states
- Its delivery network allows NovoCare Pharmacy to serve all 50 states, DC, Puerto Rico
What changes the route most are the Medicaid rules the route is affected most by Medicaid rules. Today, 10 state Medicaid programs cover GLP-1s for weight loss. Select your state to view its drug list and prior authorization rules:
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming